Lantheus Holdings, Inc. (NASDAQ:LNTH) Stake Lessened by Hood River Capital Management LLC

Hood River Capital Management LLC cut its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 37.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 758,697 shares of the medical equipment provider’s stock after selling 453,255 shares during the quarter. Hood River Capital Management LLC owned 1.09% of Lantheus worth $67,873,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in LNTH. T. Rowe Price Investment Management Inc. lifted its holdings in shares of Lantheus by 40.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider’s stock valued at $135,025,000 after buying an additional 435,445 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Lantheus in the fourth quarter valued at approximately $36,183,000. Swedbank AB grew its position in Lantheus by 53.3% in the fourth quarter. Swedbank AB now owns 1,107,243 shares of the medical equipment provider’s stock worth $99,054,000 after acquiring an additional 385,000 shares in the last quarter. Keybank National Association OH acquired a new position in shares of Lantheus during the 4th quarter worth $27,526,000. Finally, Norges Bank bought a new position in shares of Lantheus during the 4th quarter valued at $26,189,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Stock Performance

Shares of NASDAQ LNTH opened at $99.57 on Wednesday. Lantheus Holdings, Inc. has a 52 week low of $62.59 and a 52 week high of $126.89. The stock has a market capitalization of $6.82 billion, a P/E ratio of 16.57 and a beta of 0.20. The stock’s fifty day moving average is $96.11 and its 200 day moving average is $95.36.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Equities research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Truist Financial boosted their target price on shares of Lantheus from $120.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. B. Riley lowered their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research note on Friday, March 21st. Finally, JMP Securities reiterated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $129.43.

Insider Buying and Selling at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. This represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares of the company’s stock, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 63,109 shares of company stock valued at $6,016,046. Corporate insiders own 2.00% of the company’s stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.